
The 36-month CORE-VNS study findings showed sustained seizure reduction, improved quality of life, and reduced seizure-related hospitalizations among people with drug-resistant epilepsy receiving vagus nerve stimulation therapy.
Findings from a new study indicate that compared with children who were not exposed to the drug, children with in utero exposure to sodium valproate have lower scores on national tests at age 7 years.



